lipogenesis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
== Funding == Gavi runs in five-year funding cycles which enables it to negotiate long-term deals with vaccine manufacturers. Industrialised countries are Gavi's principal donors, providing approximately three-quarters of the total funding. All donor governments are represented on the Gavi Board through a constituency system (i.e. one donor country will represent several donors in their constituency). In the period of 2016–2020, Gavi received US$9.3 billion, with over half of the total funding provided by the three largest donors: the UK, the Bill & Melinda Gates Foundation (BMGF), and the USA (see table). Following the Global Vaccine Summit in June 2020 hosted in the UK, US$8.8 billion was raised for the funding cycle 2021 to 2025; exceeding the target of US$7.4 billion. This included US$2 billion from the UK, US$1.6 billion from the Gates Foundation and US$1 billion from Norway. For the 2026-2030 funding cycle, the UK announced it was committing to donate £1.25 billion (roughly US$1.7 billion), The Gates Foundation announced a US$1.6 billion contribution, and the US announced it was donating US$0. As a result, Gavi announced it would fall almost US$3 billion short of its budget aim of US$11.9 billion with a total budget of US$9 billion.
Entertainment Weekly critic Owen Gleiberman wrote that DiCaprio did not look old enough to play the part, but praised him as "a fluid and instinctive actor, with the face of a mischievous angel". The Guardian's Alex von Tunzelmann was similarly impressed with the actor's performance but found his talent wasted in the film. DiCaprio won a Golden Raspberry Award for Worst Screen Couple for the dual roles in 1999. Following the release of Titanic, and The Man in the Iron Mask, DeCaprio chose to reduce his workload "to learn to hear [his] own voice in choosing the roles" that he wanted to pursue. He said in 2000: "I have no connection with me during that whole Titanic phenomenon and what my face became around the world [...] I'll never reach that state of popularity again, and I don't expect to [...] It's not something I'm going to try to achieve either." DiCaprio was next cast to star in an earlier version of American Psycho (2000) for a reported salary of $20 million; after disagreements with Oliver Stone on the film's direction, DiCaprio left the project, taking the lead role in The Beach instead. Adapted from Alex Garland's 1996 novel, the film saw him play a backpacking American tourist who ends up in a secret island commune in the Gulf of Thailand. Budgeted at $50 million, the film earned almost three times that at the box office, but was negatively reviewed by critics, and earned him a nomination for the Golden Raspberry Award for Worst Actor. Todd McCarthy of Variety thought DiCaprio gave a compelling performance but his character lacked defining qualities.
== ECU Health-owned hospitals == ECU Health Medical Center, Greenville - Flagship Hospital ECU Health Beaufort Hospital, Washington ECU Health North Hospital, Roanoke Rapids ECU Health Bertie Hospital, Windsor ECU Health Chowan Hospital, Edenton ECU Health Duplin Hospital, Kenansville ECU Health Edgecombe Hospital, Tarboro ECU Health Roanoke-Chowan Hospital, Ahoskie The Outer Banks Hospital, Nags Head (jointly owned with Chesapeake Regional Healthcare) Former facilities:
== Biological function == NADPH oxidases (NOXes) are one of the major sources of cellular reactive oxygen species (ROS), and they still are the focus of extensive research interest due to their exclusive function in producing ROS under normal physiological conditions. The NADPH oxidase complex is dormant under normal circumstances but is activated to assemble in the membranes during respiratory burst. The activated NADPH oxidase generates superoxide which has roles in animal immune response and plant signalling. Superoxide can be produced in phagosomes which have ingested bacteria and fungi, or it can be produced outside of the cell. In macrophages, superoxide kills bacteria and fungi by mechanisms that are not yet fully understood. Superoxide spontaneously dismutates to form peroxide which is then protonated to produce hydrogen peroxide. Opinions are polarised as to how the oxidase kills microbes in neutrophils. On the one hand it is thought that hydrogen peroxide acts as substrate for myeloperoxidase to produce hypochlorous acid. It may also inactivate critical metabolic enzymes, initiate lipid peroxidation, damage iron-sulphur clusters, and liberate redox-active iron, which allows the generation of indiscriminate oxidants such as the hydroxyl radical.
Sources: en.wikipedia.org
== Sources == L. S. Ettre (2004) American Laboratory, May 2004, pages 4-6 In memoriam: Csaba Horváth A. Guttman (2000) American Laboratory, June 2000, pages 6-10 Archived 2022-05-20 at the Wayback Machine Happy Birthday Csaba Horváth The Hungary Page Nobel Prize Winners and Famous Hungarians: Science, Mathematics & Technology Yale news of his death at the Wayback Machine (archived June 17, 2004) "Speeches at his remembrance Service". Archived from the original on June 18, 2004. Retrieved September 13, 2007. Claudia Flavell-White The Chemical Engineer October 2010 pp 54–55 "Degrees of Separation: Chemical Engineers who Changed the World - Csaba Horváth" An Introduction to Separation Science, (1973) B.L. Karger, Cs. Horváth and L.R. Snyder, Wiley
== External links == Laws, ordinances, guidelines, expert opinions and publications on radiation protection Archived 2018-03-18 at the Wayback Machine, timeline since 2002 of the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection. Retrieved on November 28, 2017. Guidelines for quality assurance in radiology Archived 2013-07-15 at the Wayback Machine (PDF) German Medical Association, November 23, 2007. Retrieved December 4, 2017. DIN Radiology Standards Archived 2013-07-15 at the Wayback Machine (PDF) DIN Radiology Standards Committee NAR in cooperation with the German Radiological Society, June 2015, accessed December 4, 2017. Radiation protection in veterinary medicine - Guideline to the Radiation Protection Ordinance (StrlSchV) and the X-ray Ordinance (RöV) (PDF) September 25, 2014, Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety, Division Medical-Biological Affairs of Radiation Protection Ref. RS II 4 - 11432/7. Retrieved November 28, 2017. Radioactivity and radiation protection (PDF; 6.6 MB) Federal Office of Public Health (Switzerland), July 2007, accessed November 25, 2017. Overview of international radiation protection associations and organizations, Austrian Association for Radiation Protection. Retrieved December 3, 2017. Human Radiation Experiments DOE Openness. Retrieved January 10, 2018. Department of Energy OpenNet Resources. Retrieved January 10, 2018. Igor Gusev, Angelina Guskova, Fred A. Mettler: Medical Management of Radiation Accidents, Second Edition.
=== Nuclear Magnetic Resonance Spectroscopy === NMR spectroscopy plays a crucial role in characterizing cage formation and dynamics in solution. Solution-state NMR allows researchers to monitor reaction progress and confirm structural features through chemical shift analysis and coupling patterns. Two-dimensional NMR techniques help establish connectivity patterns and verify the successful formation of key structural features. This solution-phase characterization complements solid-state analysis by providing insight into the cage's behavior under practical application conditions.
== Products and price == Grameen Danone Foods Ltd. produces a yoghurt called Shokti Doi containing protein, vitamins, iron, calcium, zinc and other micronutrients aimed to fill nutritional deficits of children in Bangladesh. 'Shokti Doi' (which means 'strength yoghurt') is primarily intended for children. In 2017, a 50g cup sold for 10 Taka and 80g cup for 40 taka.
=== Recurring character descriptions === Racquel (Erinn Hayes) is an attractive supermom whose comfortable relationship with Joel and Sydney rubs Julia the wrong way. Racquel had attempted to kiss Joel in the past, but Joel turned her down. She has one daughter, Harmony, who was best friends with Joel and Julia's daughter, Sydney. For both of their daughters to continue their close relationship, Joel overlooks the situation and pretends the kiss never happened. Katie (Marguerite Moreau) was Crosby's girlfriend, who was putting pressure on Crosby to settle down and start a family. She was unaware of Jasmine and Jabbar until the fifth episode. She ended her relationship with Crosby after he revealed his secret about having a son. Although she was upset that he had been secretly spending time with Jabbar for a month and a half, she was more hurt that he did not introduce Jabbar to her when they met at the recording studio. Dr. Pelikan (Tom Amandes) is the doctor that diagnosed Max Braverman with Asperger's and is giving the family guidance on coping with his condition. Kristina refers Julia to Dr. Pelikan when Julia thinks her daughter may also have Asperger's Syndrome. However, Dr. Pelikan tells Julia that Sydney is gifted and acts out because she is simply bored. In season 5, Hank Rizzoli sees Dr. Pelikan when Hank suspects he has Asperger's Syndrome. Jim Kazinsky (Mike O'Malley) was Sarah's high school sweetheart. Julia sets them up on a date in the series premiere. They have a brief on again, off again relationship in season 1.
Sources: en.wikipedia.org
The venom of the Red harvester ant was used to treat rheumatism, arthritis, and poliomyelitis via the immunological reaction produced by its sting. This technique, in which ants are allowed to sting affected areas in a controlled manner, is still used in some arid rural areas of Mexico. The silkworm, Bombyx mori, was also commonly consumed both as a regional food and for medicinal purposes in Central America after it was brought to the New World by the Spanish and Portuguese. Only the immatures are consumed. Boiled pupae were eaten to treat apoplexy, aphasy, bronchitis, pneumonia, convulsions, hemorrhages, and frequent urination. The excrement produced by the larvae is also eaten to improve circulation and alleviate the symptoms of cholera (intense vomiting and diarrhea).
dihydrothymine dehydrogenase dihydrouracil dehydrogenase (NADP+) 4,5-dihydrothymine: oxidoreductase DPD DHPDH dehydrogenase, dihydrouracil (nicotinamide adenine dinucleotide, phosphate) DHU dehydrogenase hydropyrimidine dehydrogenase dihydropyrimidine dehydrogenase (NADP+)
Arabic, the second language of Somalia, is spoken by a million or two million Somalis. This is because of longstanding ties with the Arab world, the influence of Arabic media, and religious education. It is a liturgical language as the language of the Qur'an. Somalis learn Arabic from a young age with an estimated 75 percent of children being able to read and write Arabic when they join formal schools at age six to eight years. English is widely spoken and taught due to colonial legacies and globalisation. Italian was official in Italian Somaliland, but significantly diminished following independence. Other languages include Bravanese, spoken by the Bravanese people, and Kibajuni of the Bajuni people.
Christopher Layne claims that the preponderance of power has been the dominant US strategy during both the Cold War and the post-Cold War periods. "Preponderance's strategic imperatives are the same as they were during the post-World War II era: pacification and reassurance in Europe and East Asia, and protection of these regions from instability in the periphery." The post-Cold War strategy of preponderance holds that "only a preponderance of US power ensures peace" which is "the result of an imbalance of power in which US capabilities are sufficient, operating on their own, to cow all potential challengers and to comfort all coalition partners. It is not enough consequently to be primus inter pares [...] One must be primus solus." Layne since the beginning of the post-Cold war period expects the preponderance of power to trigger counterbalancing. He finds that "it was the bipolar structure of the postwar system that allowed Washington to pursue a strategy of preponderance successfully" and thereby smother the emergence of other great powers. But the preponderance of power which "others found merely irritating in a bipolar world may seem quite threatening in a unipolar world." Because of these structural factors, "an American strategy of preponderance [...] is doomed to failure"; it will "cause other states to balance against the United States". Overturning the scholarly conventional wisdom, however, the current preponderant power seems to render inoperative the counterbalancing long central to research in international relations.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.